Getting closer to ASEP's commercialization Sepsis is one of the most prevalent causes of death in the US and current industry tests require 24 hours for results to detect and confirm Sepsis.
I'm expecting that the mid-2022 commercialization of ASEP Medical's ($ASEP.CN) tests will be a massive catalyst for the stock.
The ability of the tests to be used to both treat and prevent sepsis by detecting a unique gene expression is going to be a revolutionary step for medicine and will save so many lives.
More information on sepsis and the dire need for an improved way to diagnose and treat it:
https://www.jems.com/patient-care/improving-outcomes-in-sepsis/